Kymera Therapeutics (KYMR) Q4 FY25 earnings call

Kymera Therapeutics concluded a pivotal Q4 FY25, marked by significant clinical advancements and a strengthened financial position. The company initiated Phase IIb trials for its lead STAT6 degrader, KT-621, in atopic dermatitis and asthma, building on strong Phase I data. Additionally, its first-in-class IRF5 degrader, KT-579, entered Phase I, expanding the immunology pipeline. Strategic collaborations and a substantial cash balance extending into 2029 underpin ambitious development plans for 2026 and beyond.